These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32199670)

  • 41. [The influence of ursodeoxycholic acid on some biochemical, immunologic and histopathologic parameters in patients with primary biliary cirrhosis].
    Skulina D; Owczarek D; Ciećko-Michalska I; Szczepański W; Tetnowski J; Garlicka M; Janas-Skulina U
    Przegl Lek; 1999; 56(3):201-4. PubMed ID: 10442009
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
    Shi J; Wu C; Lin Y; Chen YX; Zhu L; Xie WF
    Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An electron microscopic and morphometric study of ursodeoxycholic effect in primary biliary cirrhosis.
    Neuman MG; Cameron RG; Haber JA; Katz GG; Blendis LM
    Liver; 2002 Jun; 22(3):235-44. PubMed ID: 12100574
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Ursodeoxycholic acid combined with bezafibrate in the treatment of refractory primary biliary cholangitis: a meta-analysis].
    Feng BL; Yu HH; Shen W
    Zhonghua Gan Zang Bing Za Zhi; 2019 Apr; 27(4):304-311. PubMed ID: 31082343
    [No Abstract]   [Full Text] [Related]  

  • 45. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
    Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
    Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis.
    Yin Q; Li J; Xia Y; Zhang R; Wang J; Lu W; Zhou Y; Zheng Y; Abudumijiti H; Chen R; Chen K; Li S; Liu T; Wang F; Lu J; Zhou Y; Guo C
    Drug Des Devel Ther; 2015; 9():5407-19. PubMed ID: 26491252
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.
    Silveira MG; Lindor KD
    Clin Liver Dis; 2008 May; 12(2):425-43; x-xi. PubMed ID: 18456189
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ursodeoxycholic acid for primary biliary cirrhosis: lesson for the future?
    Gluud C; Christensen E
    J Hepatol; 2001 May; 34(5):787-8. PubMed ID: 11434634
    [No Abstract]   [Full Text] [Related]  

  • 49. Ursodeoxycholic acid for primary biliary cirrhosis.
    Lindor KD; Poupon R; Poupon R; Heathcote EJ; Therneau T
    Lancet; 2000 Feb; 355(9204):657-8. PubMed ID: 10697011
    [No Abstract]   [Full Text] [Related]  

  • 50. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
    Angulo P; Jorgensen RA; Keach JC; Dickson ER; Smith C; Lindor KD
    Hepatology; 2000 Feb; 31(2):318-23. PubMed ID: 10655252
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Efficacy of combined use of ursodeoxycholic acid and heptral in the treatment of primary biliary cirrhosis].
    Avezov SA; Mansurova FKh
    Klin Med (Mosk); 2004; 82(2):46-9. PubMed ID: 15106512
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study.
    Örnolfsson KT; Lund SH; Olafsson S; Bergmann OM; Björnsson ES
    Scand J Gastroenterol; 2019 May; 54(5):609-616. PubMed ID: 31074667
    [No Abstract]   [Full Text] [Related]  

  • 53. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
    Holtmeier J; Leuschner U
    Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current Treatment Options for Primary Biliary Cholangitis.
    Wong KA; Bahar R; Liu CH; Bowlus CL
    Clin Liver Dis; 2018 Aug; 22(3):481-500. PubMed ID: 30259848
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Finding the cure for primary biliary cholangitis - Still waiting.
    Tanaka A; Gershwin ME
    Liver Int; 2017 Apr; 37(4):500-502. PubMed ID: 28371099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study.
    Serfaty L; De Leusse A; Rosmorduc O; Desaint B; Flejou JF; Chazouilleres O; Poupon RE; Poupon R
    Hepatology; 2003 Jul; 38(1):203-9. PubMed ID: 12830003
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Past hepatitis B virus infection was not associated with poorer response or the UK-PBC risk score in ursodeoxycholic acid-treated patients with primary biliary cirrhosis.
    Hu Z; Ni P; Fan X; Men R; Yang L
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):277. PubMed ID: 30575642
    [No Abstract]   [Full Text] [Related]  

  • 59. The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study.
    Leuschner M; Holtmeier J; Ackermann H; Leuschner U
    Eur J Gastroenterol Hepatol; 2002 Dec; 14(12):1369-76. PubMed ID: 12468960
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
    Angulo P; Patel T; Jorgensen RA; Therneau TM; Lindor KD
    Hepatology; 2000 Nov; 32(5):897-900. PubMed ID: 11050036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.